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Supporting Information
Reactions were carried out at ambient temperature with exposure to air, unless otherwise noted. All reagents and solvents were purchased from commercial sources and used as received.
NMR spectra were obtained on a Bruker AV 500 MHz, 400 MHz or 300 MHz spectrometer at 25 °C. The NMR spectra were obtained from DMSO-d 6 and were referenced to the residual solvent peak ( 1 H: 2.50 ppm; 13 C: 39.5 ppm). High-resolution mass spectrometry samples were injected without column onto a Dionex 3000-Orbitrap Velos LC-MS. Flash chromatography was carried out on a Yamazen purification system using prepacked Yamazen Universal columns.
Preparative HPLC was carried out using a Phenomenex Gemini-NX 10 µm, C18 110 Å column (150 x 30 mm) using a 5% to 95% gradient of MeCN / 0.05% aqueous TFA mixture over 13 min unless another column or solvent system is noted. Drug compounds purified by preparative HPLC were assumed to be salts containing one molecule of trifluoroacetic acid (TFA).
Liquid chromatography mass spectrometry (LCMS) retention times were acquired on an Acquity UPLC BEH C8 1.7 µm 2.1 x 50 mm column, 40 in vitro cell proliferation assay were conducted using the method below. To a stirred solution of (4R)-4-phenyl-3-propanoyl-1,3-oxazolidin-2-one ( 77, 153.97, 139.97, 129.02 128.24, 126.21, 83.35, 79.61, 70.22, 60.54, 57.71, 57.60, 57.31, 51.07, 50.56, 46.39, 29.86, 28.46, 14.23 33, 172.42, 153.28, 137.74, 129.55, 128.56, 126.90, 82.39, 79.50, 60.58, S7 57.57, 57.21, 53.72, 52.20, 50.94, 50.35, 43.15, 37.19, 29.79, 28.49, 14.63 (DMAc) (1 mL) were added EDCI (7 mg, 0.04 mmol) and HOBt (2 mg, 0.01 mmol) and the mixture was stirred for 15 hours. To the mixture was added Et 2 NH (40 µL, 386.67 µmol). After 1 h, analysis by LCMS showed the reaction was complete. The reaction mixture was diluted with H 2 O and DMAc and then the mixture was purified by preparatory RP-HPLC with a Phenomenex Gemini-NX 10 µm, C18 110 Å column (150 x 30 mm) using a 5% to 95% MeCN in 0.05% aqueous TFA solution as the eluent. A total of 6 mg of the title compound was obtained as the 38, 173.90, 172.44, 169.46, 167.30, 166.43, 164.91, 137.73, 129.55, 128.98, 128.57, 128.30, 126.91, 85.77, 82.20, 80.61, 78.65, 65.99, 63.66, 60.12, 59.02, 57.89, 57.59, 57.35, 56.07, 55.30, 55.13, 53.72, 52.20, 50.97, 49.36, 43.32, 38.89, 37.48, 37.26, 32.46, 32.09, 32.01, 30.51, 29.90, 25.85, 25.13, 21.50, 20.63, 18.96, 18.90, 18.73, 18.05, 15.95, 15.95, 14. 38, 172.43, 170.27, 169.45, 167.86, 166.84, 137.79, 137.73, 129.54, 128.80, 128.56, 126.90, 124.86, 80.61, 77.61, 65.98, 60.16, 58.23, 57.90, 57.81, 57.34, 53.71, 52.80, 52.18, 51.44, 43.31, 37.19, 32.67, 32.46, 29.82, 28.82, 25.85, 18.65, 18.22, 18.04, 16.08, 15.97, 14.65, 13.42, 10.94 After insoluble materials were removed by filtration, the filtrate was concentrated under reduced pressure.
A total of 26 mg of the title compound was obtained (0.06 mmol, 97%) as a white amorphous solid that was used without further purification. To a stirred rt solution of 18 (81 mg, 0.0714 mmol) in EtOAc (500 mL) were added CMPI (100 mg, 0.391 mmol) and DIEA (62 µL, 0.36 mmol). After 16 h, analysis by LCMS showed the macrocyclic condensation reaction was complete. The mixture was evaporated to give a yellow S15 oil. 35, 172.49, 171.91, 171.69, 171.34, 166.34, 137.74, 129.58, 129.54, 128.59, 126.94, 80.33, 80.22, 65.95, 60.79, 58.53, 57.65, 57.39, 54.78, 53.74, 53.03, 52.30, 47.53, 45.88, 44.05, 41.80, 40.88, 37.16, 36.38, 36.03, 32.59, 32.43, 32.02, 31.33, 29.92, 29.77, 29.11, 25.99, 23.75, 23.43, 18.91, 18.75, 18.19, 17.81, 15.92, 14.93, 14.75, 11.47, 10.14 28, 169.78, 166.33, 165.96, 159.43, 159.06, 158.71, 158.35, 144.30, 122.75, 78.31, 72.33, 71.78, 57.54, 56.57, 53.24, 50.27, 43.07, 41.93, 41.60, 39.04, 38.23, 37.28, 32.72, 31.64, 28.92, 27.03, 25.82, 25.66, 24.01, 19.55, 16.91, 16.20, 10.90 
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